𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon therapy in chronic hepatitis C virus infection

✍ Scribed by Ola Weiland

Book ID
109332579
Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
742 KB
Volume
14
Category
Article
ISSN
1574-6976

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in antibody titers to hepatitis
Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection
✍ MD Akihiko Urushihara; Takeshi Sodeyama; Akihiro Matsumoto; Eiji Tanaka 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 804 KB

## Abstract The use of quantitative assays for hepatitis C virus specific antibodies (anti‐HCV) as a prognostic marker was evaluated in 31 patients with chronic hepatitis C treated with interferon (IFN). Changes in titers of serum HCV‐RNA and anti‐HCV antibodies; anti‐C11 (anti‐core), anti‐C100 (an

Loss of HBsAg with interferon-α therapy
Loss of HBsAg with interferon-α therapy in chronic hepatitis D virus infection
✍ Johnson Y. N. Lau; Ruth King; Christopher J. Tibbs; Adrian P. Catterall; Heather 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

Eleven patients with chronic hepatitis D virus (HDV) infection who had chronic active hepatitis and HDV antigen on liver biopsy were randomised in a crossover therapeutic trial of interferon-alpha 2b vs. no therapy. Nine patients had a history of intravenous drug use (drug free > 6 months before the

Genetic variability of hepatitis C virus
Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon–ribavirin therapy
✍ I. Vuillermoz; E. Khattab; E. Sablon; I. Ottevaere; D. Durantel; C. Vieux; C. Tr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 2 views

## Abstract Little is known about hepatitis C virus (HCV) breakthrough during antiviral therapy, although it would help in understanding HCV resistance to current antiviral treatments. To analyse the implication of virological factors and the vigour of humoral immune responses in this phenomenon, w

Breakthrough during recombinant interfer
Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management
✍ Luigi Roffi; Guido Colloredo Mels; Guido Antonelli; Giorgio Bellati; Fabio Paniz 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

Recombinant interferon alfa (r-IFNa2) has been shown to normalize the aminotransferase levels in approximately 50% of patients with chronic hepatitis C virus (HCV). Few patients experience a relapse during the treatment, in spite of a complete initial response (breakthrough). We studied 191 HCV Ab-p